This application to continue as the Statistical and Data Management Center (SDMC) for the HIV Vaccine Trials Network (HVTN) is one of three applications comprising the Leadership Group of the HVTN. The HVTN scientific agenda focuses exclusively on RFA priority number 1: 'Vaccine Researchand Development."""""""" This application describes howthe Statistical Center for HIV/AIDS Research&Prevention (SCHARP) will achieve the aims of the RFAto (1) provide statistical leadership for the design, conduct, analysis and publication of Network clinical trials/studies;(2) provide central data management capability that includes randomization, data set and case report form design, central storage, security, processing and retrieval of study results;(3) provide data management and protocol training throughout the Network;(4) provide data-focused clinical trials implementation, and operation;and (5) contribute to cross-Network efforts in developing common data elements and data interfaces. SCHARP has extensive experience in the design, conduct and analysis of global HIV vaccine and prevention studies. Thus, the systems we propose to use for data collection, managment, monitoring, and analysis are all well tested and in accordance with ICH guidelines. SCHARP statisticians will also develop and deploy novel statistical methodologies to increase the efficiency and rigor of the proposed program of HlV vaccine trials. The HIV/AIDS epidemic continues to expand in almost all regions of the world, with approximately 4.8 million new infections in 2003 (UNAIDS 2004 Report on the Global AIDS Epidemic). Finding a safe, effective vaccine that will protect persons against infection and/or disease progression is an international public- health priority. Only through clinical trials held to the highest scientific and regulatory standards willthis goal be achieved.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI068635-05
Application #
7901059
Study Section
Special Emphasis Panel (ZAI1-TH-A (J1))
Program Officer
Renzullo, Philip O
Project Start
2006-06-29
Project End
2013-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
5
Fiscal Year
2010
Total Cost
$12,347,128
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Finak, Greg; Gottardo, Raphael (2016) Promises and Pitfalls of High-Throughput Biological Assays. Methods Mol Biol 1415:225-43
Leitman, Ellen M; Hurst, Jacob; Mori, Masahiko et al. (2016) Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. J Infect Dis 214:379-89
Sun, Yanqing; Li, Mei; Gilbert, Peter B (2016) Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark. Comput Stat Data Anal 93:348-358
Deschamps, Marie M; Metch, Barbara; Morgan, Cecilia A et al. (2016) Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907. J Acquir Immune Defic Syndr 71:70-7
Koblin, Beryl A; Grant, Shannon; Frye, Victoria et al. (2015) HIV Sexual Risk and Syndemics among Women in Three Urban Areas in the United States: Analysis from HVTN 906. J Urban Health 92:572-83
Huang, Yunda; Karuna, Shelly T; Janes, Holly et al. (2015) Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine 33:749-52
Fong, Youyi; Di, Chongzhi; Permar, Sallie (2015) Change point testing in logistic regression models with interaction term. Stat Med 34:1483-94
Bart, Pierre-Alexandre; Huang, Yunda; Karuna, Shelly T et al. (2014) HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest 124:4843-56
McKinnon, Lyle R; Hughes, Sean M; De Rosa, Stephen C et al. (2014) Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study. PLoS One 9:e85675
Hopkins, Kathryn L; Laher, Fatima; Otwombe, Kennedy et al. (2014) Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One 9:e103446

Showing the most recent 10 out of 53 publications